CIAM
SPRY icon

Caitong International Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Caitong International Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47K Buy
+558
New +$4.8K ﹤0.01% 1303
2025
Q4 		– Sell
-1,687
Closed -$17K – 2342
2025
Q3 		$17K Buy
+1,687
New +$24.2K 0.01% 789
2025
Q1 		– Sell
-4,028
Closed -$42.5K – 2507
2024
Q4 		$42.5K Buy
+4,028
New +$56.4K 0.04% 537

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Caitong International Asset Management's SPRY Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 558 shares worth $4.47K. The stake represents ﹤0.01% of the portfolio and ranks #1303 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in SPRY as recently as Q3 2025.

Caitong International Asset Management first reported a position in SPRY in Q4 2024 and has held it in 3 quarters since. The position peaked at $42.5K in Q4 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Caitong International Asset Management held 558 shares of ARS Pharmaceuticals worth $4.47K as of Q2 2026.
  • ARS Pharmaceuticals was a new Caitong International Asset Management position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1303 holding.
  • Caitong International Asset Management first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Caitong International Asset Management's ARS Pharmaceuticals position peaked at $42.5K in Q4 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.